November approval decisions loom for cilta-cel and Voxzogo, while molnupiravir heads for an advisory panel.
The failure of the phase 2 Moonsong outpatient trial prompts a phase 3 rethink and a one-year delay.
But a potentially more interesting advisory committee, for Merck and Ridgeback’s molnupiravir, awaits.
Molnupiravir, a repurposed flu antiviral with a poor history, delivers in a pivotal study in Covid-19 outpatients.
A few developers are still finding reasons to research novel pandemic treatments, though much of the ongoing work is focused on proven approaches.
With a Darpin antiviral for treating Covid-19 Molecular Partners hopes to follow Vir’s regulatory path.